Press Release
MetaPay-Open the Era of Meta Payment
Since the birth of mankind, we seem to have never experienced lasting peace and prosperity. We have tried our best to build one civilization after another, but because of lack of trust and coordination, it always disappeared immediately. In the evolution of the universe, humans have walked for millions of years, but even though they have faced countless difficulties together, they still cannot understand each other in the end.
Just when we were about to lose confidence, the emergence of blockchain relighted our hopes. The greatness of decentralized consensus is that code is more reliable than human nature, and “Code is Law” can last the development of civilization. Decentralization allows independent thoughts to shine like stars, and at the same time allows trillions of individuals to reach a commendable consensus on the identification of rules and trends, and enable the collaboration between humans to reach an unprecedented height and breadth.
In the collaboration between many humans, MetaPay shines with the brightest light, guiding us towards eternity.
Why is MetaPay followed by the public?
We know that the existing global payment system relies on the establishment of various centralized governments, central banks and some third-party payment institutions. There seems to be no problem with the existing payment system, it has very fatal flaws.
Firstly, the fully centralized governance system makes the system very easy to be attacked by hackers, and once it is attacked, it will cause catastrophic consequences. Secondly, the high transfer fees and management fees have seriously harmed the interests of users. Thirdly, when it comes to cross-border transfers and payments, the speed and efficiency will be greatly reduced, which is not conducive to the development of commercial trade.
Based on these market pain points, the founding team of MetaPay put forward the idea of meta-financial payment.
Meta Finance, derived from Metaverse, is committed to the construction of virtual and real payment infrastructure，is a safe and efficient Meta financial payment ecosystem based on the Ethereum Layer 2 expansion protocol developed by genius blockchain technology geeks. The main direction is cross-chain payment and ecological construction of virtual assets, including decentralized payment , pledge, liquidity mining, NFT aggregator, etc.
The reason why MetaPay can carry the efficient and complicated payment requirements is because of its strong cryptographic algorithm. It uses the discrete logarithm encryption and elliptic curve encryption which are commonly used in modern public key crypto systems. At the same time, it uses the non-interactive zk-SNARKs zero-knowledge proof system to completely address the issue of transactions being traced to expose user privacy.
MetaPay adopts the Layer 2 technology based on Ethereum, and achieves a flash payment experience comparable to Internet products through expansion of the off-chain channel. In addition to the extremely fast payment experience, there is no handling fee in the off-chain channel, which effectively solves the problems of slow speed and high gas fee of the Ethereum.
It is mainly achieved through the following three aspects：
Two-way payment channel
Two participants create a ledger entry on the blockchain, which requires the two participants to sign any fund expenditures. Both parties create transactions that return ledger entries to their respective allocations, but do not broadcast them to the blockchain. They can update the personal distribution of ledger entries by creating many transaction expenditures from the current ledger entry output. Only the latest version is valid, which is enforced by smart contract scripts that can be analyzed by the blockchain. By broadcasting the latest version to the blockchain, any party can close the entry at any time without any trust or custody.
Lightning Network
By creating a network of two-party ledger entries, you can find a path across the network, similar to routing data packets on the Internet. The nodes on the path are not trusted because the payment is executed through a script that enforces atomicity (the entire payment succeeds or fails) by decrementing the time lock. In order to expand Lightning Network in Layer 2, MetaPay incorporates two basic protocols, RSMC (Revocable Sequential Maturity Contract) and HTLC (Hash Clocked Contract) in the transaction verification process of the underlying protocol which is to build the Fund pool on Layer 2 and the establishment of payment channels.
The Lightning Network on Layer 2 has many advantages. The first is instant determinism. As long as the signatures of all parties pass the status update, the status will be “confirmed” without waiting for block confirmation on the blockchain; Secondly, The status update is off-chain, and peer-to-peer communication can guarantee privacy. Only the final status will be submitted to the blockchain. Finally, there is a low gas fee. The Lightning Network only needs to settle and clear the fees on the blockchain when the channel is opened and closed. At other times, no matter how the two parties update in the channel, the transaction is free.
Blockchain arbitration mechanism
It is possible to conduct transactions outside the blockchain without restrictions. It is also possible to conduct off-chain transactions with the confidence that it is executable on the blockchain. This is similar to the way one person enters into many legal contracts with others, but there is no arbitration every time a contract is signed. By making transactions and scripts parseable, smart contracts can be executed on the blockchain. Only in the case of non-cooperation, arbitration will be intervened. But for blockchain, the result is certain.
There is no doubt that the technical team of MetaPay understands the pain points of the current market very well. Through the above three points, MetaPay can completely break the congestion of existing Ethereum network transactions and achieve the best transaction speed in the entire network.
The MetaPay system with advantages such as instant payment, high scalability, low cost and cross-chain will help mankind get rid of the shackles of the existing payment system and realize the ultimate dream of payment freedom.
If you think MetaPay’s planning stops at payment, then you are wrong. After completes the payment infrastructure, it will use Meta NFT as the starting point to fully deploy the metaverse ecology.
Let’s first look at the layout of Meta NFT. It aims to build the world’s largest NFT asset and financial derivatives trading platform with the richest ecology and the strongest technical strength.
Therefore, Meta NFT is integrating more than 100 animation IP and 1,000 global artists and collecting more than 5,000 contemporary artworks as a reserve. Users will be free to trade NFT assets including artwork and real estate in Meta NFT.
In addition to NFT asset trading, Meta NFT allows users to mint their custom NFT assets.
Users can directly create NFTs in Meta NFT Layer 2, and the changes in the state of the world in the system are similar to recharging NFTs. Web, Mobile App and API-based user interfaces to the Mint smart contract will be developed to make asset creation and management a simple process. The following parameters define a new custom asset:
Currently, MetaPay has completed the construction of the development team, the internal structure of the functional prototype, and is focusing on the development of the first version of MetaPay. Although the development work is still in progress, MetaPay has completed the internal angel round of fundraising and is in the process of private sales. At present, it has received preliminary investment intentions from global leading institutions such as CMS, AU21, DFG, NGC, Rarestone, LinkPad, etc.
As of press time, the MetaPay team is still intensively developing. It is believed that users will be able to directly use MetaPay and NFT asset trading shortly. We are very much to see it soon.
If you want to know lates news about MetaPay, please check following links:
MetaPay Twitter：https://twitter.com/Metapay1/
MetaPay Telegram：https://t.me/metapaygroup
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.
Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.
The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.
This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health.
Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.
About Vitiligo
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.
More About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
- The U.S. FDA approval information can be found on the Incyte official website, as follows:
- The EMA approval information can be found on the Incyte official website, as follows:
- The clinical studies information can be found on the Opzelura® official website, as follows:
https://www.opzelura.com/opzelura-prescribing-information
- China Insights Consultancy’s industrial report
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Gabriel Malkin Florida Completes 120-Mile Camino Walk with Focus, Patience, and Preparation
Florida, US, 30th January 2026, ZEX PR WIRE, Most students don’t spend the start of summer walking across northern Spain. Gabriel Malkin did. In June 2025, the Florida high school graduate completed a 120-mile stretch of the Camino de Santiago, one of the world’s oldest pilgrimage routes. It wasn’t a last-minute idea. It was a goal he had planned for, trained for, and quietly worked toward for months.
This wasn’t about adventure or social media. For Gabriel, it was about setting a physical goal and showing up for it every day.
“I didn’t want to wing it,” he said. “It was important to take it seriously.”
Gabriel’s prep started long before his flight to Europe. He built up mileage slowly, starting with short daily walks in South Florida. As the months went on, he added distance, tested gear, and paid attention to recovery. Blisters, sore muscles, and weather were all part of the process. So was building patience.
“The Camino isn’t just hard because it’s long,” Gabriel said. “It’s hard because you have to get up and do it again every day. Even when you’re tired. Even when nothing hurts and you feel fine—you still have to walk.”
The daily rhythm became its own challenge. Mornings often started before sunrise, with quiet stretches of trail through farmland, hills, and towns. Gabriel carried a small pack with essentials. Water, snacks, extra socks. No Wi-Fi. No schedule beyond the day’s distance. Just a clear goal and a few hours of steady effort.
That focus and consistency mirrors how Gabriel approaches most things. Whether he’s in class, on the tennis court, or working on saxophone tone, he tends to favor structure and repetition over shortcuts. It’s not about perfection. It’s about showing up, improving slowly, and staying with it.
“I’ve never been the fastest or the strongest at anything,” he said. “But I like knowing I’m getting better, even if it’s slow.”
Gabriel grew up in South Florida and attended Virginia Shuman Young Elementary, Pine Crest in Fort Lauderdale, and NSU University School in Davie. He played tennis, baseball, and football through different stages of school. He also spent time hiking local trails and practicing saxophone, two interests he says helped him train for the Camino more than people might expect.
“Hiking helped with endurance, obviously,” he said. “But playing music teaches you a lot about repetition and listening to your body. You learn when to push and when to pause.”
For Gabriel, the Camino wasn’t a performance or a competition. It was a quiet personal test. He kept notes during the walk, not for a blog, but to track how each day felt. When he crossed the finish line in Santiago, there was no big moment. Just a quiet sense of completion.
Now back home, Gabriel hasn’t stopped walking. He’s back to local trails, early mornings, and training logs. He’s also thinking about what comes next—college, travel, more endurance goals—but isn’t rushing anything.
“There’s no rush,” he said. “The Camino reminded me that showing up every day matters more than trying to get somewhere fast.”
Gabriel Malkin Florida continues to build habits rooted in preparation, consistency, and follow-through. Whether through athletics, academics, or music, his focus remains steady: stay curious, stay active, and finish what you start.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Jon DiPietra, a New York–based real estate valuation executive, explains why common beliefs about space and value often miss the mark.
New York, US, 30th January 2026, ZEX PR WIRE, New York City is full of opinions about real estate. Many of them are repeated so often they start to feel true. But according to Jon DiPietra, decades of hands-on valuation work tell a different story.
“You learn things you cannot see in a report,” DiPietra says. “That’s where most of these myths fall apart.”
Below are five common myths that mislead everyday people across dense urban markets, why they persist, and what actually matters instead.
Myth 1: Bigger Space Always Means Better Value
Why people believe it:
Square footage is easy to compare. Listings highlight size first, so people assume more space equals more value.
The reality:
In dense cities, efficiency matters more than size. Studies show poorly used space can reduce productivity by up to 30 percent, even when square footage increases.
As DiPietra puts it, “The goal is not to produce the highest number. The goal is to produce something that makes sense in the real world.”
Try this today:
Identify one underused area in your home or office and repurpose it for a single clear function.
Myth 2: National Data Tells You Everything You Need to Know
Why people believe it:
Online tools and national reports feel authoritative and precise.
The reality:
Real estate is hyper-local. In New York, conditions can change block by block. National averages often lag reality by months.
“Real estate is ultimately driven by people, not formulas,” DiPietra says.
Try this today:
Walk your block at different times of day. Notice noise, foot traffic, and how spaces are actually used.
Myth 3: If a Space Worked Before, It Should Still Work Now
Why people believe it:
People resist change and assume layouts age well.
The reality:
How we live and work has shifted fast. Surveys show nearly 60 percent of people say their space no longer supports how they work today.
“Clear thinking matters more than being busy,” DiPietra notes.
Try this today:
Ask one simple question: What do I actually do here every day? Adjust one thing to support that reality.
Myth 4: More Information Leads to Better Decisions
Why people believe it:
Data feels safe. More feels smarter.
The reality:
Too much information can slow decisions and increase stress. Research links information overload to poorer judgment.
DiPietra says, “More data does not always lead to better decisions.”
Try this today:
Limit yourself to three criteria when evaluating a space or decision. Ignore the rest.
Myth 5: You Need a Major Renovation to Fix a Space
Why people believe it:
Media and social platforms spotlight dramatic transformations.
The reality:
Small changes often have outsized impact. Lighting, noise reduction, and decluttering consistently rank among the highest-return improvements.
“Sometimes the simplest changes create the most lasting value,” DiPietra says.
Try this today:
Improve lighting where you spend the most time. It is one of the fastest ways to change how a space feels.
If You Only Remember One Thing
Spaces influence behavior more than most people realize. When a space creates friction, it is often a design problem, not a personal one.
Understanding how space actually functions is more valuable than following assumptions or averages.
Call to Action
Share this myth list with someone who lives or works in a dense city. Pick one practical tip above and try it today. Small changes, applied intentionally, add up.
About Jon DiPietra
Jon DiPietra is a New York–based commercial real estate valuation executive and cofounder of H&T Appraisal, the valuation group of Horvath & Tremblay. With more than 20 years of experience, he has worked across residential, commercial, mixed-use, and special-use properties, focusing on how real people actually use space.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Gabriel Malkin Florida Completes 120-Mile Camino Walk with Focus, Patience, and Preparation
Jon DiPietra Debunks 5 Real Estate Myths That Mislead New Yorkers
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release6 days ago
Knybel Network Launches Focused Growth Campaign to Help Southeast Michigan Buyers and Homeowners Win in a Competitive Housing Market
-
Press Release1 week ago
Highly Recommended by GoodNight New York: Zeagoo Patterned Shirt Becomes the Focal Point of Early Spring Outfits
-
Press Release6 days ago
New Findings Reveal a Hidden Indoor Air Quality Crisis Linked to Aging HVAC Systems and Fiberglass Ductwork Across South Florida
-
Press Release6 days ago
Stockity Arrives in Indonesia, Bringing Global Markets Closer to Local Traders
-
Press Release6 days ago
Karviva Selected to Meet with Costco Wholesale Southern California Merchants at Upcoming Local Summit
-
Press Release6 days ago
GOD55 Sports Announced as Gold Partner and Official Sports Media Partner for WPC Malaysia Series 2025-26
-
Press Release7 days ago
Rankiteo Opens Global Tender for Cyber Insurers: Exclusive Access to 5 million Enterprise Profiles and the Future of Cyber Insurance Distribution
-
Press Release7 days ago
Inside Bengaluru’s New Urban Escape: How Casasaga Is Redefining City Staycations